Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cephalosporin C is a naturally occurring beta-lactam antibiotic of the cephalosporin class, originally isolated from the fungus Acremonium chrysogenum. It was first characterized in 1961 and served as the lead compound for the development of many synthetic cephalosporins, such as cefalotin. Cephalosporin C itself has weak antibacterial activity and was never commercialized as a therapeutic drug. Its mechanism of action involves inhibition of penicillin binding proteins (PBPs), which are enzymes essential for bacterial cell wall synthesis, leading to bactericidal effects. Cephalosporins are generally used to treat various bacterial infections, especially in patients allergic to penicillins[6][9][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cephalosporin C.